Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Gilead Sciences
Current Parent Company: Gilead Sciences
Penalty: $246,750,000
Year: 2024
Date: January 19, 2024
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Gilead Sciences agreed to pay over $246 million to direct purchaser plaintiffs to settle litigation alleging it entered into an improper deal to delay the introduction of a generic version of its HIV medications.
Level of Government: federal
Action Type: private litigation
Court: Northern District of California
Civil or Criminal Case: civil
Case ID: 3:19cv2573
Case Name: In re HIV Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: California
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.